Get startedLog in
    Picture of Vanda Pharmaceuticals logo

    VNDA — Vanda Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Brief: Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S

    Picture of Vanda Pharmaceuticals logoVanda Pharmaceuticals
    10/06/2025 14:07
    June 10 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN A TRIAL EVALUATING VCA-894A IN CHARCOT-MARIE-TOOTH DISEASE TYPE 2S

Source text: ID:nPn7b8nKTa

Further company coverage: VNDA.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Vanda Pharmaceuticals

    See all news